SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.

For people having surgery unrelated to their hearts, new guidelines detail how to manage heart and stroke risks before, ...

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

Noninvasive, low‐level tragus stimulation modestly reduced blood pressure (BP) in relatively healthy people with grade 1 ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

A team at the Hübner and Diecke Labs at the Max Delbrück Center has shown how human and non-human primate hearts differ ...